Naphthyl hybrid molecular tube as well as preparation method and application thereof

By designing a naphthyl hybrid molecular tube coupled with a double naphthalene skeleton and a deep hole cavity structure, the problem of insufficient bonding ability of existing naphthalene tubes is solved, and efficient identification and bonding of larger guest molecules is achieved, especially Strong bonding of drug molecules in water.

CN118955522APending Publication Date: 2024-11-15SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410787665.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-18
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing naphthalene tube molecular framework is single and the cavity size is limited, which leads to smaller bonding capabilities for larger object molecules, making it difficult to achieve efficient identification in complex environments.

Method used

A naphthyl hybrid molecular tube was designed to connect double naphthalene through benzene ring to obtain a coupled double naphthalene skeleton, which increased the cavity size and introduced appropriate substituents at the hydrogen bond binding site to form a deep hole cavity structure. Enhance bonding capabilities.

Benefits of technology

Achieve high-strength bonding of larger guest molecules under low macrocyclic concentrations, especially in water, such as p-phenylpyrimidine, phenyltetrazine derivatives, acyclovir and pefloxacin. The bonding constant reaches 105M-1 or above, surpassing the previous performance of trans naphthalene tubes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955522A_ABST
    Figure CN118955522A_ABST
Patent Text Reader

Abstract

The invention discloses a naphthyl hybrid molecular tube and a preparation method and application thereof, the naphthyl hybrid molecular tube has a structure as shown in a formula I or a formula II: # imgabs0 #, and R1-R5 are respectively and independently selected from one of-H,-OR6 and-CH2R6; r6 is independently selected from the group consisting of a linear alkyl group having C1-10, an alkoxy group having C1-10, a terminal alkenyl group having C1-10, a terminal alkynyl group having C1-10, an ester group having C1-10, a carboxylate substituent group having C1-10, a sulfonate substituent group having C1-10, a phosphate substituent group having C1-10, a triazole cation substituent group having C10-30, and an imidazole cation substituent group having C10-30; and one of C10-30 pyridine cation substituents is selected from the group consisting of C10-30 pyridine cation substituents. The naphthyl hybrid molecular tube provided by the invention has excellent subject-object recognition property, the molecular tube is provided with a larger cavity by connecting double-naphthalene through a benzene ring, so that a larger guest molecule can be recognized, particularly, the naphthyl hybrid molecular tube shows strong bonding to an antiviral drug acyclovir and an antibacterial drug pefloxacin, and the bonding constant reaches 105M <-1 > or above.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic synthesis, and in particular to a naphthyl hybrid molecular tube and a preparation method and application thereof. Background Art

[0002] Molecular recognition is ubiquitous in nature, and water-phase molecular recognition is the basis for most life activities. Research on water-phase molecular recognition plays a key role in deepening the understanding of biochemical reactions, promoting environmental monitoring and protection, promoting the development of chemistry and materials science, improving clinical diagnosis, ensuring food safety and drug development, as well as nanotechnology and sensor development.

[0003] Macrocyclic compounds are widely used as hosts in molecular recognition. Traditional macrocyclic hosts such as cyclodextrins, cucurbiturils, and calixarene can achieve molecular recognition in the aqueous phase through the driving force of hydrophobic effect. However, due to the complexity of the aqueous phase environment, the influence of solvent effects, and the diversity of polar molecular structures, traditional macrocyclic molecules are difficult to achieve efficient recognition of guest molecules and related applications in complex environments.

[0004] Naphthalene tubes are macrocyclic molecules obtained by connecting and bridging binary naphthalene skeletons through functional groups. Their structural characteristics are similar to biological receptor cavities: hydrogen bond binding sites are located in hydrophobic cavities, which provide a relatively non-polar environment for hydrogen bond interactions and avoid competition with water molecules. The synergistic effect of hydrophobic effect and hydrogen bonding enhances the interaction between host and guest molecules. However, the molecular skeleton of naphthalene tubes currently constructed is relatively simple, and due to the limitation of cavity size, the bonding to some larger guest molecules is relatively small.

[0005] Therefore, the prior art still needs to be improved and developed. Summary of the invention

[0006] In view of the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide a naphthyl hybrid molecular tube and a preparation method and application thereof, aiming to solve the problem that the existing naphthalene tube has a single molecular skeleton and a limited cavity size resulting in smaller bonding of larger guest molecules.

[0007] The technical solution of the present invention is as follows:

[0008] In a first aspect of the present invention, a naphthyl hybrid molecular tube is provided, having a structure as shown in the following formula I or formula II:

[0009]

[0010] Among them, R 1 -R 5 are independently selected from -H, -OR 6 、-CH2R 6 One of;

[0011] R 6 Independently selected from 1-10 A straight chain alkyl group with C 1-10 Alkoxy, with C 1-10 The terminal olefin group has C 1-10 The terminal alkynyl group has C 1-10 The ester group has C 1-10 The carboxylate substituent has C 1-10 Sulfonate substituents, having C 1-10 The phosphate substituent has a C 10-30 The triazolidine cation substituent has C 10-30 The imidazolium cation substituent has C 10-30 One of the substituents of the pyridinium cation.

[0012] In a preferred technical solution, the carboxylate substituent is selected from one of -CH2CO2M, -(CH2)2CO2M, -(CH2)3CO2M, -(CH2)4CO2M, -(CH2)5CO2M, -(CH2)6CO2M, -(CH2)7CO2M, -(CH2)8CO2M, and -(CH2)9CO2M; wherein M is Na, K, or NH4.

[0013] According to a preferred technical solution, the sulfonate substituent is selected from one of -CH2SO3M, -(CH2)2SO3M, -(CH2)3SO3M, -(CH2)4SO3M, -(CH2)5SO3M, -(CH2)6SO3M, -(CH2)7SO3M, -(CH2)8SO3M, and -(CH2)9SO3M; wherein M is Na, K, or NH4.

[0014] According to a preferred technical solution, the phosphate substituent is selected from one of -CH2PO3M2, -(CH2)2PO3M2, -(CH2)3PO3M2, -(CH2)4PO3M2, -(CH2)5PO3M2, -(CH2)6PO3M2, -(CH2)7PO3M2, -(CH2)8PO3M2, and -(CH2)9PO3M2; wherein M is Na, K, or NH4.

[0015] In a preferred technical solution, the triazole cation substituent is selected from One of the following; wherein a is an integer from 0 to 5, R 7 A cationic substituent.

[0016] A preferred technical solution is that the imidazolium cation substituent is selected from One of the following; wherein b is an integer from 0 to 5, R 8 A cationic substituent.

[0017] A preferred technical solution is that the pyridinium cation substituent is selected from One of the following; wherein c is an integer from 0 to 5, R 9 A cationic substituent.

[0018] In a preferred technical solution, the naphthyl hybrid molecular tube has one of the following structures:

[0019]

[0020] The second aspect of the present invention provides a method for preparing the naphthyl hybrid molecular tube as described in the first aspect, wherein the synthesis route of the naphthyl hybrid molecular tube is as follows:

[0021]

[0022] The third aspect of the present invention provides an application of the naphthyl hybrid molecular tube as described in the first aspect in molecular recognition, drug analysis or environmental monitoring.

[0023] The preferred technical solution is that the naphthyl hybrid molecular tube is used to identify compounds in purified water, and the structure of the compound is as follows:

[0024]

[0025] Beneficial effects: The naphthyl hybrid molecular tube provided by the present invention has a deep cavity structure, which has hydrogen bonding sites in the cavity, and the hydrogen bonds are shielded in this relatively non-polar deep cavity environment. In this way, on the one hand, the strength of the hydrogen bond can be less weakened, and on the other hand, the competition of water molecules for the hydrogen bonding sites is avoided. Therefore, the naphthyl hybrid molecular tube provided by the present invention can simultaneously utilize hydrophobic effects and hydrogen bonds to identify the molecules to be detected, greatly increasing the bonding ability to the guest molecules. When the concentration of the macrocycle is low, it can still bond with the molecules to be detected. When the concentration of the molecules to be detected is low, it can also bond with the molecules to be detected with high strength. The water-soluble naphthyl hybrid molecular tube I-3 exhibits a bonding constant of 10 for phenylpyrimidine and phenyltetrazine derivatives. 5 M -1 In addition, the bonding constant of I-3 to the antiviral drug acyclovir and the antibacterial drug pefloxacin is also 10 5 M -1 Above, this is a strong bond that the previous trans-naphthalene tube did not show. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1This is the H NMR spectrum of the naphthyl hybrid molecular tube I-1.

[0027] Figure 2 This is the H NMR spectrum of the naphthyl hybrid molecular tube I-2.

[0028] Figure 3 This is the H NMR spectrum of the naphthyl hybrid molecular tube I-3.

[0029] Figure 4 This is the H NMR spectrum of the naphthyl hybrid molecular tube I-4.

[0030] Figure 5 This is the H NMR spectrum of naphthyl hybrid molecular tube II-3.

[0031] Figure 6 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G7.

[0032] Figure 7 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G10.

[0033] Figure 8 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G11.

[0034] Fig. 9 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G13.

[0035] Fig.10 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G14.

[0036] Fig.11 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G16.

[0037] Fig.12 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G17.

[0038] Fig.13 This is the result of the recognition test of the naphthyl hybrid molecular tube I-3 on the guest molecule G18.

[0039] Fig.14 This is the recognition test result of trans-naphthalene tube anti-NT to the guest molecule G17.

[0040] Fig.15 This is the recognition test result of trans-naphthalene tube anti-NT to the guest molecule G18.

[0041] Fig.16 These are four configurations / conformation diagrams of naphthyl hybrid molecular tubes.

[0042] Fig.17 This is the variable temperature H NMR spectrum of the naphthyl hybrid molecular tube I-2.

[0043] Fig.18 This is the variable temperature H NMR spectrum of the naphthyl hybrid molecular tube I-4.

[0044] Fig.19 This is a comparison of the variable temperature H-NMR spectra of naphthyl hybrid molecular tubes I-2 and I-4. DETAILED DESCRIPTION

[0045] The present invention provides a naphthyl hybrid molecular tube and its preparation method and application. To make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0046] The embodiment of the present invention provides a naphthyl hybrid molecular tube having a structure shown in the following formula I or formula II:

[0047]

[0048] Among them, R 1 -R 5 are independently selected from -H, -OR 6 、-CH2R 6 One of;

[0049] R 6 Independently selected from 1-10 A straight chain alkyl group with C 1-10 Alkoxy, with C 1-10 The terminal olefin group has C 1-10 The terminal alkynyl group has C 1-10 The ester group has C 1-10 The carboxylate substituent has C 1-10 Sulfonate substituents, having C 1-10 The phosphate substituent has a C 10-30 The triazolidine cation substituent has C 10-30 The imidazolium cation substituent has C 10-30 One of the substituents of the pyridinium cation.

[0050] Specifically, the naphthyl hybrid molecular tube of this embodiment connects dinaphthalene through a benzene ring to obtain a coupled dinaphthalene skeleton. The two naphthalene faces on the skeleton can rotate freely along the benzene-naphthalene single bond, so that the cavity in the molecular tube is larger than that of the reported trans-naphthalene tube, thereby improving its bonding with larger guest molecules, enriching the types of naphthalene tube molecules, and can be used to identify more guest molecules.

[0051] In one embodiment, the straight chain alkyl group is selected from -CH3, -C2H5, -C3H7, -C4H9, -C5H 11 、-C6H 13 、-C7H 15 、-C8H 17 、-C9H 19 , -C 10 H 21 One of them.

[0052] In one embodiment, the alkoxy group is selected from -OCH3, -OC2H5, -OC3H7, -OC4H9, -OC5H 11 、-OC6H 13 、-OC7H 15 、-OC8H 17 、-OC9H 19 、-OC 10 H 21 One of them.

[0053] In one embodiment, the terminal olefin group is selected from one of -CH2C=CH, -(CH2)2C=CH2, -(CH2)3C=CH2, -(CH2)4C=CH2, -(CH2)5C=CH2, -(CH2)6C=CH2, -(CH2)7C=CH2, and -(CH2)8C=CH2.

[0054] In one embodiment, the terminal alkynyl group is selected from one of -CH2C≡CH, -(CH2)2C≡CH, -(CH2)3C≡CH, -(CH2)4C≡CH, -(CH2)5C≡CH, -(CH2)6C≡CH, -(CH2)7C≡CH, and -(CH2)8C≡CH.

[0055] In one embodiment, the ester group is selected from -CH2CO2CH3, -CH2CO2CH2CH3, -CH2CO2(CH2)2CH3, -CH2CO2(CH2)3CH3, -CH2CO2(CH2)4CH3, -CH2CO2(CH2)5CH3, -CH2CO2(CH2)6CH3, -CH2CO2(CH2)7CH3, -(CH2)2CO2CH3, -(CH2)3CO2CH3, -(CH2)4CO2CH3, -O(CH2)5CO2CH3, -(CH2)6CO2CH3, -(CH2)7CO2CH3, -(CH2)2CO2CH2CH3, -(CH2)2CO2(CH2)2CH3, -(CH2)2CO2(CH2)3CH3, -(CH2)2CO2(CH2)4CH3, -(CH2)2CO2(CH2)5CH3 H2)5CH3, -(CH2)2CO2(CH2)6CH3, -(CH2)3CO2CH2CH3, -(CH2)3CO2(CH2)2CH3, -(CH2)3CO2(CH2 )3CH3, -(CH2)3CO2(CH2)4CH3, -(CH2)3CO2(CH2)5CH3, -(CH2)4CO2CH2CH3, -(CH2)4CO2(CH2)2 One of CH3, -(CH2)4CO2(CH2)3CH3, -(CH2)4CO2(CH2)4CH3, -(CH2)5CO2CH2CH3, -(CH2)5CO2(CH2)2CH3, -(CH2)5CO2(CH2)3CH3, -(CH2)6CO2CH2CH3, -(CH2)6CO2(CH2)2CH3, and -(CH2)7CO2CH2CH3.

[0056] In one embodiment, the carboxylate substituent is selected from one of -CH2CO2M, -(CH2)2CO2M, -(CH2)3CO2M, -(CH2)4CO2M, -(CH2)5CO2M, -(CH2)6CO2M, -(CH2)7CO2M, -(CH2)8CO2M, and -(CH2)9CO2M; wherein M is Na, K, or NH4.

[0057] In one embodiment, the sulfonate substituent is selected from one of -CH2SO3M, -(CH2)2SO3M, -(CH2)3SO3M, -(CH2)4SO3M, -(CH2)5SO3M, -(CH2)6SO3M, -(CH2)7SO3M, -(CH2)8SO3M, and -(CH2)9SO3M; wherein M is Na, K, or NH4.

[0058] In one embodiment, the phosphate substituent is selected from one of -CH2PO3M2, -(CH2)2PO3M2, -(CH2)3PO3M2, -(CH2)4PO3M2, -(CH2)5PO3M2, -(CH2)6PO3M2, -(CH2)7PO3M2, -(CH2)8PO3M2, and -(CH2)9PO3M2; wherein M is Na, K, or NH4.

[0059] In one embodiment, the triazolidine cation substituent is selected from One of the following; wherein a is an integer from 0 to 5, R 7 A cationic substituent.

[0060] In one embodiment, the imidazolium cation substituent is selected from One of the following; wherein b is an integer from 0 to 5, R 8 A cationic substituent.

[0061] In one embodiment, the pyridinium cation substituent is selected from One of the following; wherein c is an integer from 0 to 5, R 9 A cationic substituent.

[0062] In one embodiment, the cationic substituent, i.e., R 7 , R 8 , R 9, are independently selected from -C(CH2CO2M)3, -C((CH2)2CO2M)3, -C((CH2)3CO2M)3, -C((CH2)4CO2M)3, -C((CH2)5CO2M)3, -C(CH2OCH2CO2M)3, -C(CH2O(CH2)2CO2M)3, -C(CH2O(CH2)3CO2M)3, -C((CH2)2OCH2CO 2M)3, -C((CH2)2O(CH2)2CO2M)3, -C((CH2)3OCH2CO2M)3, -C(CH2SO3M)3, -C((CH2)2SO3M)3, - C((CH2)3SO3M)3, -C((CH2)4SO3M)3, -C((CH2)5SO3M)3, -C(CH2OCH2SO3M)3, -C(CH2O(CH2)2SO 3M)3, -C(CH2O(CH2)3SO3M)3, -C((CH2)2OCH2SO3M)3, -C((CH2)2O(CH2)2SO3M)3, -C((CH2)3O CH2SO3M)3, -C(CH2PO3M2)3, -C((CH2)2PO3M2)3, -C((CH2)3PO3M2)3, -C((CH2)4PO3M2)3, -C(( One of -C(CH2)5PO3M2)3, -C(CH2OCH2PO3M2)3, -C(CH2O(CH2)2PO3M2)3, -C(CH2O(CH2)3PO3M2)3, -C((CH2)2OCH2PO3M2)3, -C((CH2)2O(CH2)2PO3M2)3, -C((CH2)3OCH2PO3M2)3; wherein M is Na, K or NH4.

[0063] In one embodiment, the naphthyl hybrid molecular tube has one of the following structures:

[0064]

[0065] The embodiment of the present invention provides a method for preparing the naphthyl hybrid molecular tube as described above, wherein the synthesis route of the naphthyl hybrid molecular tube is as follows:

[0066]

[0067] In one embodiment, the synthetic route of the naphthyl hybrid molecular tube is specifically as follows:

[0068]

[0069] An embodiment of the present invention provides an application of the naphthyl hybrid molecular tube as described above in molecular recognition, drug analysis or environmental monitoring.

[0070] In one embodiment, the naphthyl hybrid molecular tube is used to identify compounds in purified water, and the structure of the compound is as follows:

[0071]

[0072] The present invention will be further described below by means of specific examples.

[0073] Example 1

[0074] This embodiment provides a naphthyl hybrid molecular tube I-1, and the preparation method thereof is as follows:

[0075]

[0076] The synthesis of intermediate A5 refers to the literature (Nat. Chem., 2019, 11, 470), and the synthesis of M1 refers to (Chem.-AEur. J., 2016, 22, 14988).

[0077] Synthesis of M2: In a 1L two-necked flask, 3,5-dibromoanisole (2.61 g, 8.01 mmol), M1 (10 g, 32.04 mmol) and potassium carbonate (5.31 g, 38.45 mmol) were dissolved in DMF (500 mL) under argon, and tetrakis(triphenylphosphine)palladium (0.93 g, 0.80 mmol) was added. The mixed solution was stirred at 90°C for 12 h. After the reaction was completed, potassium carbonate solid was removed by suction filtration. After the DMF was removed from the filtrate, sodium chloride solution and ethyl acetate were added for extraction 3 times. The crude product was purified by column chromatography to obtain M2 (white solid, 3.39 g, yield 89%). 1 H NMR(500MHz,CD2Cl2)δ8.95(d,J=8.5Hz,2H),8.21(d,J=7.5Hz,2H),8.10(d,J=8.5Hz,2H),7.65-7.61(m,2H),7 .56(d,J=7.5Hz,2H),7.55-7.51(m,2H),7.19(t,J=1.5Hz,1H),7.14(d,J=1.5Hz,2H),4.00(s,6H),3.91(s,3H).

[0078] Synthesis of M3: In a 250mL two-necked flask, M2 (2.00g, 4.20mmol) and sodium hydroxide (3.36g, 84.01mmol) were dissolved in a mixed solution of water (30mL), methanol (60mL) and tetrahydrofuran (60mL). After stirring at room temperature for 10h under argon, the organic solvent in the reaction solution was removed, concentrated hydrochloric acid was added, the product precipitated, filtered and collected, and vacuum dried to obtain M3 (white solid, 1.79g, yield 95%). 1 H NMR (500MHz, DMSO-d6) δ13.56(s,2H),8.95(d,J=8.5Hz,2H),8.19(d,J=7.5Hz,2H),8.05(d,J=8. 5Hz,2H),7.72-7.58(m,6H),7.19(d,J=1.5Hz,2H),7.13(s,1H),3.89(s,3H).ESI-TOF-HRMS:m / z calcd for[MH] - Chemical Formula:C 29 H 19 O5 - ,447.1252; found 447.1238 (error=-3.1ppm).

[0079] Synthesis of I-1: Under argon, a solution of M3 (1.0 g, 2.23 mmol) and PyBOP (3.68 g, 7.08 mmol) dissolved in ultra-dry DMF (60 mL) and a solution of A5 (1.82 g, 2.23 mmol) dissolved in ultra-dry DMF (60 mL) were slowly added to a 1L two-necked bottle containing ultra-dry DMF (500 mL), DIEA (4.71 g, 36.46 mmol), and PyBOP (3.68 g, 7.08 mmol) via a syringe pump. After reacting at 50°C for 48 hours, the reaction solution precipitated a crude product in ice water. After collection by filtration and purification by column chromatography, the naphthyl hybrid molecular tube I-1 (340 mg, yield 15%) was obtained. 1H NMR(500MHz, CD2Cl2)δ8.38(d,J=9.5Hz,2H),8.30(d,J=8.0Hz,2H),7.80-7.74(m,4H),7.49-7.44(m,2H) ,7.40(d,J=7.5Hz,2H),7.39-7.35(m,2H),7.22(d,J=1.5Hz,2H),7.15(dd,J=9.5,7.0Hz,4H),7.11(d,J=7 .5Hz,2H),6.21(s,1H),5.83(s,1H),5.58(t,J=4.5Hz,2H),5.23(s,1H),5.08(d,J=4.5Hz,4H),4.72(d,J =3.5Hz,4H),4.11-3.99(m,4H),3.96(s,3H),2.42-2.33(m,2H),1.16(t,J=7.0Hz,6H).ESI-TOF-HRMS:m / z calcd for[M+H] + Chemical Formula:C 62 H 51 N2O 11 + ,999.3469; found999.3487(error=-1.8ppm).

[0080] The H NMR spectrum of I-1 is as follows Figure 1 shown.

[0081] Example 2

[0082] This embodiment provides a naphthyl hybrid molecular tube I-2, and the preparation method thereof is as follows:

[0083]

[0084] Synthesis of M4: In a 250mL two-necked flask, 3,5-dibromophenol (1.50g, 5.95mmol), M1 (5.58g, 17.86mmol) and potassium carbonate (4.94g, 35.73mmol) were dissolved in ethanol (100mL) under argon, and tetrakis(triphenylphosphine)palladium (0.69g, 0.60mmol) was added. The mixed solution was stirred at 90°C for 12h. After the reaction was completed, the potassium carbonate solid was removed by suction filtration. After the ethanol was removed from the filtrate, sodium chloride solution and ethyl acetate were added for extraction 3 times. The crude product was purified by column chromatography to obtain M4 (white solid, 2.19g, yield 75%). M4, mp: 175°C. 1H NMR (500MHz, CD2Cl2) δ8.93(d,J=10.5Hz,2H),8.19(d,J=7.5Hz,2H),8.10(d,J=8.5Hz,2H),7.64-7.60(m,2H),7.56-7.50(m,4 H),7.17(t,J=1.5Hz,1H),7.07(d,J=1.5Hz,2H),5.57(s,1H),4.47(q,J=7.0Hz,4H),1.46(t,J=7.0Hz,6H).ESI-TOF-HRMS:m / z calcd for[MH] - Chemical Formula:C 32 H 25 O5 - ,489.1707; found 489.1714 (error=+1.4ppm).

[0085] Synthesis of M5: M4 (1.8 g, 3.67 mmol), potassium carbonate (2.03 g, 14.68 mmol) and N,N-dimethylformamide (200 mL) were added to a 500 mL two-necked flask. After stirring at 50 °C for 1 h under argon, 3-bromopropyne (1.31 g, 11.01 mmol) was added through a dropping funnel. After stirring for 12 hours, the reaction solution was precipitated in 1 L of ice water, and the crude product was obtained by suction filtration. It was purified by column chromatography to obtain M5 (light brown solid, 1.8 g, yield 93%). M5, mp: 3 °C. 1 H NMR(500MHz,CD2Cl2)δ8.96(d,J=9.5Hz,2H),8.21(d,J=7.5Hz,2H),8.12(d, J=6.5Hz,2H),7.65-7.62(m,2H),7.57(d,J=7.5Hz,2H),7.55-7.51(m,2H),7 .27(t,J=1.5Hz,1H),7.22(d,J=1.5Hz,2H),4.83(d,J=2.0Hz,2H),4.47(q,J =7.0Hz,4H),2.64(t,J=2.5Hz,1H),1.46(t,J=7.0Hz,6H).ESI-TOF-HRMS:m / z calcd for[M+H] + Chemical Formula:C 35 H 29 O5 + ,529.2010; found529.2015(error=+0.9ppm).

[0086] Synthesis of M6: In a 250 mL two-necked flask, M5 (1.80 g, 3.41 mmol) and sodium hydroxide (2.72 g, 68.10 mmol) were dissolved in a mixed solution of water (30 mL), methanol (60 mL) and tetrahydrofuran (60 mL). After stirring at room temperature for 10 h under argon, the organic solvent in the reaction solution was removed, concentrated hydrochloric acid was added, the product precipitated, filtered and collected, and vacuum dried to obtain M6 (white solid, 1.40 g, yield 87%). M6, mp: 146 ° C. 1 H NMR (500MHz, DMSO-d6) δ13.42(br,2H),8.97(d,J=8.5Hz,2H),8.19(d,J=7.5Hz,2H),8.09(d,J=10.0Hz,2H),7.72-7.6 0(m,6H),7.27(d,J=1.5Hz,2H),7.20(t,J=1.5Hz,1H),4.98(d,J=2.5Hz,2H),3.71(t,J=2.5Hz,1H).ESI-TOF-HRMS:m / z calcd for[MH] - Chemical Formula:C 31 H 19 O5 - ,471.1238; found471.1236(error=-0.4ppm).

[0087] Synthesis of I-2: Under argon, a solution of M6 (1.2 g, 2.54 mmol) and PyBOP (4.19 g, 8.06 mmol) dissolved in ultra-dry DMF (60 mL) and a solution of A5 (2.07 g, 2.54 mmol) dissolved in ultra-dry DMF (60 mL) were slowly added to a 1L two-necked bottle containing ultra-dry DMF (500 mL), DIEA (5.37 g, 41.52 mmol), and PyBOP (4.19 g, 8.06 mmol) through a syringe pump. After reacting at 50°C for 48 hours, the reaction solution precipitated a crude product in ice water. After collection by filtration and purification by column chromatography, the naphthyl hybrid molecular tube I-2 (600 mg, yield 23%) was obtained. I-2, mp: 210°C. 1H NMR(500MHz, CD2Cl2)δ8.39(d,J=9.5Hz,2H),8.32(d,J=8.5Hz,2H),7.84-7.75(m,4H),7.50-7.45(m,2H),7.44 -7.35(m,4H),7.30(d,J=1.5Hz,2H),7.18-7.13(m,4H),7.12(d,J=7.5Hz,2H),6.22(s,1H),5.91(t,J=1.5Hz,1 H),5.60(t,J=4.5Hz,2H),5.23(t,J=3.5Hz,1H),5.09(d,J=4.5Hz,4H),4.88(d,J=2.0Hz,2H),4.73(d,J=3.5Hz ,4H),4.15-3.93(m,4H),2.66(t,J=2.5Hz,1H),2.38(t,J=3.0Hz,2H),1.16(t,J=7.0Hz,6H).ESI-TOF-HRMS:m / z calcd for[M+H] + Chemical Formula:C 64 H 51 N2O 11 + ,1023.3487; found 1023.3502 (error=+1.5ppm).

[0088] The H NMR spectrum of I-2 is as follows Figure 2 shown.

[0089] Example 3

[0090] This embodiment provides a naphthyl hybrid molecular tube I-3, and the preparation method thereof is as follows:

[0091]

[0092] Synthesis of I-click: In a 500mL two-necked flask, I-2 (500mg, 0.49mmol) was dissolved in ultra-dry tetrahydrofuran (200mL), and PMDETA (85mg, 0.49mmol), hyperbranched side chain M7 (364mg, 0.68mmol) and cuprous bromide (70mg, 0.49mmol) were added, and the mixture was reacted at 50°C for 18h under argon. After the reaction, cuprous bromide was removed by a silica gel column, and then purified by column chromatography to obtain hyperbranched macrocyclic I-click (723mg, yield 95%). I-click, mp:>300°C. 1H NMR (500MHz, CD2Cl2) δ8.39(d,J=9.5Hz,2H),8.31(d,J=8.5Hz,2H),8.06(s,1H),7.79(t,J=8.0Hz,4H),7.50-7.44(m,2H),7.43 -7.36(m,4H),7.34(d,J=1.5Hz,2H),7.18-7.13(m,4H),7.12(d,J=7.0Hz,2H),6.21(d,J=1.5Hz,1H),5.88(t,J=1.5Hz,1H),5.5 9(t,J=4.5Hz,2H),5.28(s,2H),5.23(t,J=3.5Hz,1H),5.09(d,J=4.5Hz,4H),4.72(d,J=3.5Hz,4H),4.12-3.99(m,4H),3.97(s, 6H),3.65(t,J=6.0Hz,6H),2.41(t,J=6.0Hz,6H),2.38(t,J=2.5Hz,2H),1.39(s,27H),1.16(t,J=7.0Hz,6H).ESI-TOF-HRMS:m / z calcd for[M+2H] 2+ Chemical Formula:C 89 H 97 N5O 20 2+ ,777.8358; found 777.8356 (error=-0.3ppm).

[0093] Synthesis of I-3: In a 100mL eggplant-shaped bottle, add I-click (50mg, 32μmol) and dichloromethane (30mL), add 4mL trifluoroacetic acid under ice bath, and react at room temperature for 8h. After the reaction is completed, remove the organic solvent, add water to precipitate the product, and filter to obtain a white solid. Then dissolve the obtained white solid in methanol (20mL), tetrahydrofuran (20mL) and water (10mL), add sodium hydroxide solid (26mg, 0.64mmol), and react at room temperature overnight. After the reaction is completed, spin off the organic solvent, add dilute hydrochloric acid, the product precipitates, collects by suction, and puts it into a vacuum oven to dry. Then dissolve the dried solid (40mg, 30.4μmol) in 1mL sodium hydroxide solution (1.2mg, 30.4μmol), dry it with a freeze dryer, and obtain a light yellow water-soluble naphthyl hybrid molecular tube I-3 (39mg, yield 85%). I-3, mp:>300℃. 1H NMR (500MHz, D2O / DMSO-d6=9:1)δ8.62(d,J=10.0Hz,2H),8.40(s,1H),8.11(br,2H),7.83-7. 73(m,4H),7.57(t,J=7.5Hz,2H),7.51(br,2H),7.44(d,J=1.5Hz,2H),7.40(d,J=7.5Hz,2H),7 .29-7.21(m,6H),6.33(s,1H),5.74(s,1H),5.48(s,1H),5.45(s,2H),5.02(br,4H),4.52(s,4 H),3.99(s,6H),3.62(t,J=7.0Hz,6H),2.43(s,2H),2.32(t,J=6.5Hz,6H).ESI-TOF-HRMS:m / z calcd for[M+4H-5Na] - Chemical Formula:C 37 H 62 N5O 20 - ,1328.3994; found 1328.3988(error=-0.5ppm).

[0094] The H NMR spectrum of I-3 is as follows Figure 3 shown.

[0095] Example 4

[0096] This embodiment provides a naphthyl hybrid molecular tube I-4, and the preparation method thereof is as follows:

[0097]

[0098] Synthesis of S3: A 1L two-necked flask was added with a magnet, 1,3-dimethoxy-2,4-dibromobenzene (2.44 g, 8.24 mmol), S1 (9.3 g, 32.96 mmol), potassium carbonate (5.47 g, 39.55 mmol) and 500 mL N, N-dimethylformamide. After replacing the argon three times, tetrakistriphenylphosphine palladium (0.95 g, 0.82 mmol) was added from the side of the two-necked flask. The gas was then pumped and ventilated three times, and the reaction was continued at 90°C overnight. After the reaction was completed, the reaction solution was filtered through diatomaceous earth to remove potassium carbonate, the filtrate was dried, and the crude product was purified by column chromatography to obtain S3 (yellow solid, 3.5 g, yield 95%). S3, mp: 202°C. 1H NMR (400MHz, CDCl3) δ10.42,10.41(s,2H),9.34,9.33(d,J=8.4,2H),8.03,8.01(d,J=4.8Hz,2H),7.88-7.81(m,2H),7.72-7. 65(m,2H),7.64-7.60(m,2H),7.58-7.51(m,2H),7.22,7.22(s,1H),6.80,6.80(s,1H),3.83,3.83(s,6H).ESI-TOF-HRMS:m / z calcd for[M+H] + Chemical Formula:C 30 H 23 O4 + ,447.1591; found 447.1586 (error=-1.1ppm).

[0099] Synthesis of S8: Add a magnetic particle, S3 (3.5 g, 7.84 mmol), and 100 mL of dichloromethane to a 250 mL reaction bottle, and drop boron tribromide (19.64 g, 78.4 mmol) with a dropping funnel under an ice bath. After reacting for 5 hours, add water to quench under an ice bath and extract with dichloromethane. Remove dichloromethane after drying and proceed directly to the next step. Add a magnetic particle, potassium carbonate (5.2 g, 37.63 mmol) and 120 mL of N, N-dimethylformamide to the spin-dried crude product to replace argon. After stirring at 50 ° C for 1 hour, add ethyl bromoacetate (3.93 g, 23.52 mmol) through a dropping funnel. React at 50 ° C overnight. After the reaction is completed, the product is precipitated in ice water from the reaction solution, filtered and purified by column chromatography to obtain S8 (yellow solid, 2.2 g, yield 48%). S8, mp: 73 ° C. 1 H NMR (500MHz, CDCl3) δ10.42,10.42(s,2H),9.33,9.32(d,J=3.0Hz,2H),8.04,8.02(d,J=4.5Hz,2H),7.95-7.90(m,2H),7.72-7.66(m,4H) ,7.59-7.53(m,2H),7.29,7.29(s,1H),6.58,6.57(s,1H),4.54-4.51(m,4H),4.25-4.18(m,4H),1.25(t,J=7.0Hz,6H).ESI-TOF-HRMS:m / z calcd for[M+H] + Chemical Formula:C 36 H 31 O8 +,591.2013; found 591.2004 (error=-1.5ppm).

[0100] Synthesis of S9: Add a magnetic particle, S8 (1.06 g, 1.79 mmol), aminosulfonic acid (1.04 g, 10.75 mmol), water (30 mL), acetone (30 mL), and tetrahydrofuran (40 mL) to a 100 mL reaction bottle, and dropwise add a sodium chlorite solution (810 mg, 8.96 mmol) dissolved in a small amount of water under an ice bath, and react at room temperature for 8 hours. After the reaction is completed, spin off the organic solvent in the reaction solution, add a large amount of water, stir, and the product precipitates. After suction filtration, dry to obtain S9 (white solid, 1.09 g, yield 98%). S9, mp: 214 ° C. 1 H NMR (500MHz, DMSO-d6) δ8.88,8.87(d,J=3.0Hz,2H),8.14-8.09(m,2H),7.85-7.80(m,2H),7.64-7.58(m,2H),7.56-7.50( m,4H),7.13,7.12(s,1H),6.82,6.81(s,1H),4.88-4.76(m,4H),4.16-4.06(m,4H),1.20-1.15(m,6H).ESI-TOF-HRMS:m / z calcd for[MH] - Chemical Formula:C 36 H 29 O 10 - ,621.1766; found 621.1766 (error=0ppm).

[0101] Synthesis of I-4: Under argon, a solution of S9 (1 g, 1.61 mmol) and PyBOP (2.66 g, 5.11 mmol) dissolved in ultra-dry DMF (60 mL) and a solution of A5 (1.31 g, 1.61 mmol) dissolved in ultra-dry DMF (60 mL) were slowly added to a 1L two-necked bottle containing ultra-dry DMF (400 mL), DIEA (3.40 g, 26.32 mmol), and PyBOP (2.66 g, 5.11 mmol) via a syringe pump. After reacting at 50°C for 48 hours, the reaction solution was poured into water and the product precipitated. The precipitate was collected by filtration and purified by column chromatography to obtain a white mixture of isomers of naphthyl hybrid molecular tube I-4 (570 mg, yield 30%). I-4, mp:>300°C. 1H NMR (500MHz, CD2Cl2) δ8.55,8.45(d,J=8.5Hz,1H),8.41,8.39(d,J=3.5Hz,2H),8.15,8.12(d,J=8.5Hz,1H),7.91 ,7.85(d,J=9.5Hz,1H),7.76-7.68(m,2H),7.64,7.62(s,1H),7.57-7.46(m,1H),7.46-7.16(m,8H),7.16-7.00(m, 3H),6.57,6.53(s,1H),6.27,6.21,6.17(s,1H),6.12,6.08,6.01(s,1H),5.68-5.59(m,2H),5.28-5.20(m,1H),5 .18-5.05(m,4H),4.88-4.56(m,8H),4.25-3.81(m,9H),2.45-2.34(m,2H),1.27-1.11(m,12H).ESI-TOF-HRMS:m / z calcd for[M+H] + Chemical Formula:C 69 H 61 N2O 16 + ,1173.4016; found1173.4037(error=-1.8ppm).

[0102] The H NMR spectrum of I-4 is as follows Figure 4 shown.

[0103] Example 5

[0104] This embodiment provides a naphthyl hybrid molecular tube II-3, and the preparation method thereof is as follows:

[0105]

[0106] The synthesis of intermediate A6 refers to literature (Nat. Chem., 2019, 11, 470).

[0107] Synthesis of S10: Add magnetic particle, S8 (1.1g, 2.46mmol), tert-butyl carbamate (1.44g, 12.32mmol) and 30mL dichloromethane, 20mL acetonitrile to a 100mL two-necked bottle, add triethylsilane (2.01g, 17.24mmol) and 1.2mL trifluoroacetic acid with a syringe after ventilation, and react for 6h. After the reaction is completed, the solvent is spin-dried and washed with acetonitrile. The washed filter cake is dissolved in 30mL dichloromethane, 5mL trifluoroacetic acid is added, and the reaction is continued for 6h. After the reaction is completed, the solvent is spin-dried, the crude product is diluted with a small amount of methanol, and then an appropriate amount of dichloromethane is added, and then a saturated sodium bicarbonate solution is added for washing, extracted with dichloromethane and spin-dried, and the residual solvent is pumped out with an oil pump to obtain S10 (yellow solid, 0.9g, yield 62%). 1 H NMR (500MHz, CDCl3) δ8.10(d,J=7.5Hz,2H),7.91(t,J=9.0Hz,2H),7.60-7.52(m,2H),7.52-7.42(m,6H),7.27(s,1H),6.61( d,J=10.0Hz,1H),4.96(t,J=5.5Hz,2H),4.82(d,J=5.0Hz,4H),4.50(s,4H),4.26-4.18(m,4H),1.28(dd,J=7.0,4.0Hz,6H).

[0108] Synthesis of II-3: Under argon, a solution of A6 (406 mg, 0.66 mmol) and PyBOP (1.09 g, 2.09 mmol) dissolved in ultra-dry DMF (50 mL) and a solution of S10 (391 mg, 0.66 mmol) dissolved in ultra-dry DMF (50 mL) were slowly added to a 1L two-necked bottle containing ultra-dry DMF (400 mL), DIEA (1.39 g, 10.76 mmol), and PyBOP (1.09 g, 2.09 mmol) by a syringe pump. After reacting at 50°C for 48 hours, the reaction solution was poured into water and the product precipitated. The precipitate was collected by filtration and purified by column chromatography to obtain a white naphthyl hybrid molecular tube II-3 isomer mixture (193 mg, yield 25%). 1H NMR(500MHz,CD2Cl2)δ8.34-8.20(m,2H),8.17-7.96(m,2H),7.84-7.64( m,2H),7.64-7.56(m,2H),7.54-7.46(m,2H),7.43-7.21(m,7H),7.12-6.9 1(m,4H),6.60-6.56(m,1H),6.22-6.18(m,1H),6.18-6.16(m,1H),6.06-5 .42(m,4H),5.28-5.11(m,2H),4.82-4.50(m,8H),4.24-4.01(m,8H),2.56 -2.35(m,2H),1.28-1.13(m,12H).

[0109] The H NMR spectrum of II-3 is as follows Figure 5 shown.

[0110] Performance Testing

[0111] The host-guest performance test of the naphthyl hybrid molecular tube obtained in the example is carried out as follows:

[0112] The water-soluble naphthyl hybrid molecular tube I-3 prepared in Example 3 was used to identify hydrophilic polar molecules. The bonding constants (K) of I-3 with phenylpyrimidine and phenyltetrazine derivatives, heterocyclic compounds and some drugs in water were determined by isothermal titration calorimetry (ITC). a ), test data such as Figure 6-13 As shown in Table 1. The reported trans-naphthalene tube anti-NT was used as a comparative example to determine its bonding constant (K a ), test data such as Figure 14-15 And as shown in Table 2.

[0113] The specific structure of the guest molecule is as follows:

[0114]

[0115] The specific structure of trans-naphthalene tube is as follows:

[0116]

[0117] Isothermal titration calorimeter model: Malvern MicroCal PEAQ-ITC Automated instrument; solvent: ultrapure water; temperature: 25°C.

[0118] Table 1: Host-guest performance test results of naphthyl hybrid molecular tube I-3

[0119] object <![CDATA[Binding constant (K a / M -1 )]]> G7 <![CDATA[1.7×10 5 ]]> G10 <![CDATA[1.6×10 5 ]]> G11 <![CDATA[3.1×10 4 ]]> G13 <![CDATA[5.6×10 3 ]]> G14 <![CDATA[1.6×10 3 ]]> G16 <![CDATA[7.0×10 2 ]]> G17 <![CDATA[1.1×10 5 ]]> G18 <![CDATA[3.5×10 5 ]]>

[0120] Table 2: Host-guest performance test results of anti-NT

[0121] object <![CDATA[Bonding constant (K a / M -1 )]]> G17 <![CDATA[8.9×10 3 ]]> G18 <![CDATA[7.6×10 4 ]]>

[0122] It can be seen from the data in Table 1 that the naphthyl hybrid molecular tube I-3 can highly identify important organic small molecules with biological and medical significance in water, such as phenylpyrimidine derivatives (G7), phenyltetrazine derivatives (G8), drug intermediates (G11), antituberculosis drug pyrazinamide (G13), anticancer drug tirapazamine (G14), antiviral drug acyclovir (G17) and antibacterial drug pefloxacin (G18). In addition, the water-soluble naphthyl hybrid molecular tube I-3 can identify the environmental pollutant 1,4-dioxane (G16) that is miscible with water, indicating that it can well identify hydrophilic molecules in water. Comparing the data in Table 1 and Table 2, it can be seen that compared with the previous trans-naphthalene tube, the naphthyl hybrid molecular tube of the present invention has an order of magnitude greater bonding constant for the antiviral drug acyclovir (G17) and the antibacterial drug pefloxacin (G18).

[0123] Configuration / conformation studies

[0124] Traditional naphthalene tube molecules are constructed from a bridged binaphthalene skeleton, and the external acetal oxygen bridge of the bridged binaphthalene locks the structure, which limits the research on the configuration / conformation of the naphthalene tube to a certain extent. Compared with the naphthalene tube constructed solely from bridged binaphthalene, the naphthyl hybrid molecular tube in the present invention exhibits a rich configuration / conformation. The two naphthalene faces on the coupled binaphthalene skeleton that constructs the naphthyl hybrid molecular tube can rotate freely along the benzene-naphthalene single bond, thereby forming four macrocyclic molecules with different configurations / conformations including a pair of enantiomers, that is, the two naphthalene faces are the same up, the same down, or one up and one down, as shown in detail. Fig.16 shown.

[0125] During the experiment, it was found that the specific position of the side chain on the phenyl-coupled naphthalene structure can affect the configuration and conformation of the naphthalene hybrid daughter tube. Taking I-2 and I-4 in Examples 2 and 4 as examples, the influence of the coupled naphthalene skeleton tail chain on the configuration / conformation of the naphthalene tube is explained: In the structure of I-2, R 3 =R 5 =H, R 4 =OCH2C≡CH; in the structure of I-4, R 3 =R 5 =OCH2CO2Et, R 4=H. Among them, the room temperature NMR hydrogen spectrum of I-2 has only one set of signals, while each proton of I-4 has three sets of signals. After analysis, the two naphthalene faces of I-2 can flip freely in dichloromethane solution at room temperature and change conformations quickly, so that the protons show a set of peaks in the NMR spectrum; while I-4 is hindered from rotating freely due to the steric hindrance of the ortho-OCH2COOEt substituent and the cavity, thus forming a rotation isomer, that is, there are four isomers. The variable temperature NMR results of I-2 are as follows Fig.17 As shown, the temperature-dependent NMR results of I-4 are as follows Fig.18 As shown, Fig.17 and Fig.18 confirm this conclusion.

[0126] The variable temperature NMR results of I-2 and I-4 are more specific. Fig.19 shown. Fig.19 In the figure, on the left is the variable temperature NMR of I-2. As the temperature decreases, the signals of the amide proton 1, acetal oxygen bridge proton 2 and phenyl proton 3 pointing to the cavity gradually become wider and become a broad peak at about -30°C. When the temperature is further reduced to -60°C, it is observed that all the above hydrogens are split into three groups of peaks, indicating that the isomers cannot quickly convert to each other at this temperature. As for the variable temperature NMR of I-4, it was found that the three groups of peaks of its protons did not merge when the temperature rose to 90°C, and only slightly shifted, confirming that the naphthalene face of I-4 cannot rotate freely. Therefore, it can be concluded that during the conformational isomerization of I-2, due to the steric hindrance of the macrocyclic cavity, the naphthalene face can be flipped from the outside and the conformation can change; and when the ortho position of the phenyl is substituted by a substituent, four atropisomers can be formed. This configuration / conformation of the naphthyl hybrid molecular tube, which can be regulated by the tail chain and cavity steric hindrance, is a unique property that the previously reported naphthalene tubes cannot exhibit.

[0127] In summary, the present invention provides a naphthyl hybrid molecular tube having a structure shown in Formula I or Formula II. The naphthyl hybrid molecular tube of the present invention has a cavity feature similar to that of a biological receptor: the hydrogen bonding site is located in a hydrophobic cavity, and the hydrophobic cavity provides a relatively non-polar environment for hydrogen bonding interactions, which can avoid competition with water molecules, and the synergistic effect of the hydrophobic effect and the hydrogen bonding effect enhances the interaction between the host and guest molecules. In addition, the present invention obtains a coupled binaphthalene skeleton by connecting binaphthalene with a benzene ring, and the two naphthalene faces on the skeleton can rotate freely along the benzene-naphthalene single bond, so that the cavity in the molecular tube is larger than that of the reported trans-naphthalene tube, thereby improving its bonding with larger guest molecules, enriching the types of naphthalene tube molecules, and can be used to identify more guest molecules. Among them, the water-soluble naphthyl hybrid molecular tube I-3 can identify neutral molecules, polar small molecules and drug molecules in water, especially the antiviral drug acyclovir and the antibacterial drug pefloxacin, showing strong bonding, and the bonding constant reaches 10 5 M-1 above.

[0128] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. A naphthyl hybrid molecular tube, characterized in that: It has the structure shown in the following formula I or formula II: Among them, R 1 -R 5 are independently selected from -H, -OR 6 、-CH2R 6 One of; R 6 Independently selected from 1-10 A straight chain alkyl group with C 1-10 Alkoxy, with C 1-10 The terminal olefin group has C 1-10 The terminal alkynyl group has C 1-10 The ester group has C 1-10 The carboxylate substituent has a C 1-10 Sulfonate substituents, having C 1-10 The phosphate substituent has a C 10-30 The triazolium cation substituent has C 10-30 The imidazolium cation substituent has C 10-30 One of the substituents of the pyridinium cation.

2. The naphthyl hybrid molecular tube according to claim 1, characterized in that: The carboxylate substituent is selected from one of -CH2CO2M, -(CH2)2CO2M, -(CH2)3CO2M, -(CH2)4CO2M, -(CH2)5CO2M, -(CH2)6CO2M, -(CH2)7CO2M, -(CH2)8CO2M, and -(CH2)9CO2M; wherein M is Na, K, or NH4.

3. The naphthyl hybrid molecular tube according to claim 1, characterized in that: The sulfonate substituent is selected from one of -CH2SO3M, -(CH2)2SO3M, -(CH2)3SO3M, -(CH2)4SO3M, -(CH2)5SO3M, -(CH2)6SO3M, -(CH2)7SO3M, -(CH2)8SO3M, and -(CH2)9SO3M; wherein M is Na, K, or NH4.

4. The naphthyl hybrid molecular tube according to claim 1, characterized in that: The phosphate substituent is selected from one of -CH2PO3M2, -(CH2)2PO3M2, -(CH2)3PO3M2, -(CH2)4PO3M2, -(CH2)5PO3M2, -(CH2)6PO3M2, -(CH2)7PO3M2, -(CH2)8PO3M2, and -(CH2)9PO3M2; wherein M is Na, K, or NH4.

5. The naphthyl hybrid molecular tube according to claim 1, characterized in that: The triazole cation substituent is selected from One of the following; wherein a is an integer from 0 to 5, R 7 A cationic substituent.

6. The naphthyl hybrid molecular tube according to claim 1, characterized in that: The imidazolium cation substituent is selected from One of the following; wherein b is an integer from 0 to 5, R 8 is a cationic substituent; And / or, the pyridinium cation substituent is selected from One of the following; wherein c is an integer from 0 to 5, R 9 A cationic substituent.

7. The naphthyl hybrid molecular tube according to claim 1, characterized in that: The naphthyl hybrid molecular tube has one of the following structures:

8. A method for preparing a naphthyl hybrid molecular tube according to any one of claims 1 to 7, characterized in that: The synthetic route of the naphthyl hybrid molecular tube is as follows:

9. Use of the naphthyl hybrid molecular tube as claimed in any one of claims 1 to 7 in molecular recognition, drug analysis or environmental monitoring.

10. The use according to claim 9, characterized in that: The naphthyl hybrid molecular tube is used to identify compounds in purified water, and the structure of the compound is as follows: